Biomarker & Intervention Discovery
Breast Cancer
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs1.37MWHO GHE 2021 · all ages
Global DALYs22.85MWHO GHE 2021 · worldwide
US mortality48.9K deaths/yrWHO GHE 2021
Global mortality701.9K deaths/yrWHO GHE 2021 · worldwide
NIH funding$757MFY2025 · RCDC estimate
Funding levelModerate
Spontaneous remissionSpontaneous regression documented but rare (<0.5%); 5-year survival stage I: ~99%; stage IV: ~28% overall, improving…
Best-intervention remissionHER2+ metastatic: pertuzumab + trastuzumab + docetaxel (CLEOPATRA: 57.1-month median OS vs 40.8 months); HR+/HER2-…
Gap sizeVaries greatly by subtype; HER2+ and HR+ have dramatically improved outcomes; TNBC lags; metastatic remains incurable…
Primary barrierbiological (metastatic) + access (treatment disparities by race/SES)
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous regression documented but rare (<0.5%); 5-year survival stage I: ~99%; stage IV: ~28% overall, improving with modern therapy
Best-intervention remission
HER2+ metastatic: pertuzumab + trastuzumab + docetaxel (CLEOPATRA: 57.1-month median OS vs 40.8 months); HR+/HER2- with CDK4/6 inhibitors: 63-month PFS in first-line (MONALEESA-2); TNBC with pembrolizumab + chemotherapy: 23-month OS vs 16.1 months; pCR with neoadjuvant: 80-90% in HER2+ with dual HER2 blockade
Gap size
Varies greatly by subtype; HER2+ and HR+ have dramatically improved outcomes; TNBC lags; metastatic remains incurable in most patients
Primary barrier
biological (metastatic) + access (treatment disparities by race/SES)
Racial disparities in breast cancer mortality persist (Black women 40% higher mortality despite similar incidence); access to genetic testing (BRCA1/2) and CDK4/6 inhibitors varies significantly; germline testing vastly underutilised
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Breast Cancer” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."